|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1973
|
|
gptkbp:ATCCode
|
gptkb:J01DB04
|
|
gptkbp:brand
|
gptkb:cefazolin
|
|
gptkbp:CASNumber
|
25953-19-9
|
|
gptkbp:chemicalFormula
|
C14H14N8O4S3
|
|
gptkbp:contraindication
|
hypersensitivity to cephalosporins
|
|
gptkbp:discoveredBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:drugClass
|
first-generation cephalosporin
|
|
gptkbp:eliminationHalfLife
|
1.8 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:indication
|
gptkb:skin_infection
urinary tract infection
respiratory tract infection
surgical prophylaxis
bone and joint infection
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits bacterial cell wall synthesis
|
|
gptkbp:molecularWeight
|
454.5 g/mol
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:routeOfAdministration
|
intramuscular
intravenous
|
|
gptkbp:sideEffect
|
nausea
diarrhea
allergic reaction
rash
|
|
gptkbp:synonym
|
gptkb:Kefzol
cefazolin sodium
|
|
gptkbp:usedFor
|
gptkb:Bacteria
|
|
gptkbp:bfsParent
|
gptkb:cefazolin
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ancef
|